natgillin/translations-raw huggingface dataset:
The most frequently (seen in ≥ 1% of patients ) reported adverse reactions associated with the use of olanzapine in clinical trials were somnolence, weight gain, eosinophilia, elevated prolactin, cholesterol, glucose and triglyceride levels (see section 4.4), glucosuria, increased appetite, dizziness, akathisia, parkinsonism, leukopenia, neutropenia (see section 4.4), dyskinesia, orthostatic hypotension, anticholinergic effects, transient asymptomatic elevations of hepatic aminotransferases (see section 4.4), rash, asthenia, fatigue, pyrexia, arthralgia, increased alkaline phosphatase, high gamma glutamyltransferase, high uric acid, high creatine phosphokinase and oedema.
Najčešće prijavljene nuspojave (uočene u ≥ 1% bolesnika) povezane s primjenom olanzapina u kliničkim ispitivanjima bile su somnolencija, povećanje tjelesne težine, eozinofilija, povišene vrijednosti prolaktina, kolesterola, glukoze i triglicerida (vidjeti dio 4.4), glikozurija, povećan apetit, omaglica, akatizija, parkinsonizam parkinsonizam, leukopenija, neutropenija (vidjeti dio 4.4), diskinezija, ortostatska hipotenzija, antikolinergički učinci, prolazni asimptomatski porasti vrijednosti jetrenih aminotransferaza (vidjeti dio 4.4), osip, astenija, umor, pireksija, artralgija, povišena razina alkalne fosfataze, visoka razina gama glutamiltransferaze, visoka razina mokraćne kiseline, visoka razina kreatin fosfokinaze i edem.
The most frequently (seen in ≥ 1% of patients ) reported adverse reactions associated with the use of olanzapine in clinical trials were somnolence, weight gain, eosinophilia, elevated prolactin, cholesterol, glucose and triglyceride levels (see section 4.4), glucosuria, increased appetite, dizziness, akathisia, parkinsonism, leukopenia, neutropenia (see section 4.4), dyskinesia, orthostatic hypotension, anticholinergic effects, transient asymptomatic elevations of hepatic aminotransferases (see section 4.4), rash, asthenia, fatigue, pyrexia, arthralgia, increased alkaline phosphatase, high gamma glutamyltransferase, high uric acid, high creatine phosphokinase and oedema.
Najčešće prijavljivane nuspojave povezane s primjenom olanzapina u kliničkim ispitivanjima (uočene u ≥ 1% bolesnika) bile su: somnolencija, povećanje tjelesne težine, eozinofilija, povišena razina prolaktina, kolesterola, glukoze i triglicerida (vidjeti dio 4.4), glikozurija, pojačan tek, omaglica, akatizija, parkinsonizam, leukopenija, neutropenija (vidjeti dio 4.4), diskinezija, ortostatska hipotenzija, antikolinergički učinci, prolazna asimptomatska povišenja jetrenih aminotransferaza (vidjeti dio 4.4), osip, astenija, umor, pireksija, artralgija, povišena razina alkalne fosfataze, visoka razina gama glutamiltransferaze, visoka razina mokraćne kiseline, visoka razina kreatin fosfokinaze i edem.
The most frequently (seen in ≥ 1% of patients ) reported adverse reactions associated with the use of olanzapine in clinical trials were somnolence, weight gain, eosinophilia, elevated prolactin, cholesterol, glucose and triglyceride levels (see section 4.4), glucosuria, increased appetite, dizziness, akathisia, parkinsonism, leukopenia, neutropenia (see section 4.4), dyskinesia, orthostatic hypotension, anticholinergic effects, transient asymptomatic elevations of hepatic aminotransferases (see section 4.4), rash, asthenia, fatigue, pyrexia, arthralgia, increased alkaline phosphatase, high gamma glutamyltransferase, high uric acid, high creatine phosphokinase and oedema.
Najčešće zabilježene nuspojave (uočene u ≥1 % bolesnika) povezane s primjenom olanzapina u kliničkim ispitivanjima bile su somnolencija, povećanje tjelesne težine, eozinofilija, povišene vrijednosti prolaktina, kolesterola, glukoze i triglicerida (vidjeti dio 4.4), glukozurija, povećan apetit, omaglica, akatizija, parkinsonizam, leukopenija, neutropenija (vidjeti dio 4.4), diskinezija, ortostatska hipotenzija, antikolinergički učinci, prolazni asimptomatski porast razina jetrenih aminotransferaza (vidjeti dio 4.4), osip, astenija, umor pireksija, artralgija, povišena razina alkalne fosfataze, visoka razina gama glutamiltransferaze, visoka razina mokraćne kiseline, visoka razina kreatin fosfokinaze i edemi.
The most frequently (seen in ≥ 1% of patients ) reported adverse reactions associated with the use of olanzapine in clinical trials were somnolence, weight gain, eosinophilia, elevated prolactin, cholesterol, glucose and triglyceride levels (see section 4.4), glucosuria, increased appetite, dizziness, akathisia, parkinsonism, leukopenia, neutropenia (see section 4.4), dyskinesia, orthostatic hypotension, anticholinergic effects, transient asymptomatic elevations of hepatic aminotransferases (see section 4.4), rash, asthenia, fatigue, pyrexia, arthralgia, increased alkaline phosphatase, high gamma glutamyltransferase, high uric acid, high creatine phosphokinase and oedema.
Najčešće zabilježene nuspojave (uočene u ≥1 % bolesnika) povezane s primjenom olanzapina u kliničkim ispitivanjima bile su somnolencija, povećanje tjelesne težine, eozinofilija, povišene vrijednosti prolaktina, kolesterola, glukoze i triglicerida (vidjeti dio 4.4), glukozurija, povećan apetit, omaglica, akatizija, parkinsonizam, leukopenija, neutropenija (vidjeti dio 4.4), diskinezija, ortostatska hipotenzija, antikolinergički učinci, prolazni asimptomatski porast razina jetrenih aminotransferaza (vidjeti dio 4.4), osip, astenija, umor, pireksija, artralgija, povišena razina alkalne fosfataze, visoka razina gama glutamiltransferaze, visoka razina mokraćne kiseline, visoka razina kreatin fosfokinaze i edemi.
The most frequently (seen in ≥ 1% of patients ) reported adverse reactions associated with the use of olanzapine in clinical trials were somnolence, weight gain, eosinophilia, elevated prolactin, cholesterol, glucose and triglyceride levels (see section 4.4), glucosuria, increased appetite, dizziness, akathisia, parkinsonism, leukopenia, neutropenia (see section 4.4), dyskinesia, orthostatic hypotension, anticholinergic effects, transient asymptomatic elevations of hepatic aminotransferases (see section 4.4), rash, asthenia, fatigue,pyrexia, arthralgia, increased alkaline phosphatase, high gamma glutamyltransferase, high uric acid, high creatine phosphokinase and oedema.
Najčešće zabilježene nuspojave (uočene u ≥1 % bolesnika) povezane s primjenom olanzapina u kliničkim ispitivanjima bile su somnolencija, povećanje tjelesne težine, eozinofilija, povišene vrijednosti prolaktina, kolesterola, glukoze i triglicerida (vidjeti dio 4.4), glukozurija, povećan apetit, omaglica, akatizija, parkinsonizam, leukopenija, neutropenija (vidjeti dio 4.4), diskinezija, ortostatska hipotenzija, antikolinergički učinci, prolazni asimptomatski porast razina jetrenih aminotransferaza (vidjeti dio 4.4), osip, astenija, umor, pireksija, artralgija, povišena razina alkalne fosfataze, visoka razina gama glutamiltransferaze, visoka razina mokraćne kiseline, visoka razina kreatin fosfokinaze i edemi.
The most frequently (seen in ≥ 1% of patients) reported adverse reactions associated with the use of olanzapine in clinical trials were somnolence, weight gain, eosinophilia, elevated prolactin, cholesterol, glucose and triglyceride levels (see section 4.4), glucosuria, increased appetite, dizziness, akathisia, parkinsonism, leukopenia, neutropenia (see section 4.4), dyskinesia, orthostatic hypotension, anticholinergic effects, transient asymptomatic elevations of hepatic aminotransferases (see section 4.4), rash, asthenia, fatigue, pyrexia, arthralgia, increased alkaline phosphatase, high gamma glutamyltransferase, high uric acid, high creatine phosphokinase and oedema.
Najčešće prijavljene nuspojave (uočene u ≥ 1% bolesnika) povezane s primjenom olanzapina u kliničkim ispitivanjima bile su somnolencija, povećanje tjelesne težine, eozinofilija, povišene vrijednosti prolaktina, kolesterola, glukoze i triglicerida (vidjeti dio 4.4), glikozurija, povećan apetit, omaglica, akatizija,parkinsonizam, leukopenija, neutropenija (vidjeti dio 4.4), diskinezija, ortostatska hipotenzija, antikolinergički učinci, prolazni asimptomatski porasti vrijednosti jetrenih aminotransferaza (vidjeti dio 4.4), osip, astenija, umor, pireksija, artralgija, povišena razina alkalne fosfataze, visoka razina gama glutamiltransferaze, visoka razina mokraćne kiseline, visoka razina kreatin fosfokinaze i edem.
The most frequently (seen in ≥ 1% of patients) reported adverse reactions associated with the use of olanzapine in clinical trials were somnolence, weight gain, eosinophilia, elevated prolactin, cholesterol, glucose and triglyceride levels (see section 4.4), glucosuria, increased appetite, dizziness, akathisia, parkinsonism, leukopenia, neutropenia (see section 4.4), dyskinesia, orthostatic hypotension, anticholinergic effects, transient asymptomatic elevations of hepatic aminotransferases (see section 4.4), rash, asthenia, fatigue, pyrexia, arthralgia, increased alkaline phosphatase, high gamma glutamyltransferase, high uric acid, high creatine phosphokinase and oedema.
Najčešće zabilježene nuspojave (uočene u ≥1 % bolesnika) povezane s primjenom olanzapina u kliničkim ispitivanjima bile su somnolencija, povećanje tjelesne težine, eozinofilija, povišene vrijednosti prolaktina, kolesterola, glukoze i triglicerida (vidjeti dio 4.4), glukozurija, povećan apetit, omaglica, akatizija, parkinsonizam, leukopenija, neutropenija (vidjeti dio 4.4), diskinezija, ortostatska hipotenzija, antikolinergički učinci, prolazni asimptomatski porast razina jetrenih aminotransferaza (vidjeti dio 4.4), osip, astenija, umor, pireksija, artralgija, povišena razina alkalne fosfataze, visoka razina gama glutamiltransferaze, visoka razina mokraćne kiseline, visoka razina kreatin fosfokinaze i edemi.
The most frequently (seen in ≥ 1% of patients) reported adverse reactions associated with the use of olanzapine in clinical trials were somnolence, weight gain, eosinophilia, elevated prolactin, cholesterol, glucose and triglyceride levels (see section 4.4), glucosuria, increased appetite, dizziness, akathisia, parkinsonism, leukopenia, neutropenia (see section 4.4), dyskinesia, orthostatic hypotension, anticholinergic effects, transient asymptomatic elevations of hepatic aminotransferases (see section 4.4), rash, asthenia, fatigue, pyrexia, arthralgia, increased alkaline phosphatase, high gamma glutamyltransferase, high uric acid, high creatine phosphokinase and oedema.
Najčešće zabilježene nuspojave (uočene u ≥1 % bolesnika) povezane s primjenom olanzapina u kliničkim ispitivanjima bile su somnolencija, povećanje tjelesne težine, eozinofilija, povišene vrijednosti prolaktina, kolesterola, glukoze i triglicerida (vidjeti dio 4.4), glukozurija, povećan apetit, omaglica, akatizija, parkinsonizam, leukopenija, neutropenija (vidjeti dio 4.4), diskinezija, ortostatska hipotenzija, antikolinergički učinci, prolazni asimptomatski porast vrijednosti jetrenih aminotransferaza (vidjeti dio 4.4), osip, astenija, umor, pireksija, artralgija, povišena razina alkalne fosfataze, visoka razina gama glutamiltransferaze, visoka razina mokraćne kiseline, visoka razina kreatin fosfokinaze i edem.
The most frequently (seen in ≥ 1% of patients) reported adverse reactions associated with the use of olanzapine in clinical trials were somnolence, weight gain, eosinophilia, elevated prolactin, cholesterol, glucose and triglyceride levels (see section 4.4), glucosuria, increased appetite, dizziness, akathisia, parkinsonism, leukopenia, neutropenia (see section 4.4), dyskinesia, orthostatic hypotension, anticholinergic effects, transient asymptomatic elevations of hepatic aminotransferases (see section 4.4), rash, asthenia, fatigue, pyrexia, arthralgia, increased alkaline phosphatase, high gamma glutamyltransferase, high uric acid, high creatine phosphokinase and oedema.
Najčešće zabilježene nuspojave (uočene u ≥1 % bolesnika) povezane s primjenom olanzapina u kliničkim ispitivanjima bile su somnolencija, povećanje tjelesne težine, eozinofilija, povišene vrijednosti prolaktina, kolesterola, glukoze i triglicerida (vidjeti dio 4.4), glukozurija, povećan apetit, omaglica, akatizija, parkinsonizam, leukopenija, neutropenija (vidjeti dio 4.4), diskinezija, ortostatska hipotenzija, antikolinergički učinci, prolazni asimptomatski porast vrijednosti jetrenih aminotransferaza (vidjeti dio 4.4), osip, astenija, umor, pireksija, artralgija, povišena razina alkalne fosfataze, visoka razina gama glutamiltransferaze, visoka razina mokraćne kiseline, visoka razina kreatin fosfokinaze i edemi.
The most frequently observed ADRs in patients receiving Arzerra in clinical trials were infusion- related reactions which occurred in 68% (348/511) of patients at any time during treatment.
Najčešće primijećene nuspojave na lijek u bolesnika liječenih ofatumumabom u kliničkim ispitivanjima bile su reakcije povezane s infuzijom, koje su se javile u 68% (348/511) bolesnika u nekom trenutku tijekom liječenja.
The most frequently observed ADRs in patients receiving ofatumumab in clinical trials were infusion- related reactions which occurred in 68% (348/511) of patients at any time during treatment.
Najčešće primijećene nuspojave na lijek u bolesnika liječenih ofatumumabom u kliničkim ispitivanjima bile su reakcije povezane s infuzijom, koje su se javile u 68% (348/511) bolesnika u nekom trenutku tijekom liječenja.
The most frequently observed adverse drug reactions (ADRs) in patients receiving Gazyvaro were IRRs, which occurred predominantly during infusion of the first 1,000 mg.
Najčešće primijećene nuspojave u bolesnika liječenih lijekom Gazyvaro bile su reakcije na infuziju, a javljale su se prvenstveno tijekom infuzije prvih 1000 mg.
The most frequently observed adverse drug reactions (ADRs) in patients receiving MabThera were IRRs which occurred in the majority of patients during the first infusion.
Najčešće opažene nuspojave u bolesnika liječenih lijekom MabThera bile su reakcije povezane s infuzijom, koje su se u većine bolesnika pojavile pri prvoj infuziji.
The most frequently observed adverse drug reactions (ADRs) reported in ≥ 5 % of patients in two double-blind, long-term trials of Abilify Maintena were weight increased (9.0 %), akathisia (7.9 %), insomnia (5.8 %), and injection site pain (5.1 %).
Najčešće opažene nuspojave zabilježene u ≥ 5 % bolesnika u dva dvostruko slijepa dugotrajna ispitivanja lijeka Abilify Maintena bile su povećanje tjelesne težine (9,0 %), akatizija (7,9 %), nesanica (5,8 %) i bol na mjestu injekcije (5,1 %).
The most frequently observed adverse drug reactions (≥30%) in patients receiving Stivarga are asthenia/fatigue, hand foot skin reaction, diarrhoea, decreased appetite and food intake, hypertension, dysphonia and infection.
Najčešće opažene nuspojave (≥ 30%) u bolesnika koji su primali lijek Stivarga su astenija/umor, kožna reakcija na šakama i stopalima, proljev, smanjeni apetit i uzimanje hrane, hipertenzija, disfonija i infekcija.
The most frequently observed adverse drug reactions in patients treated with delamanid (i.e. incidence > 10%) are nausea (38.3%), vomiting (33%), and dizziness (30.2%).
Najčešće uočene nuspojave na lijek u bolesnika liječenih delamanidom (primjerice, incidencija > 10%) su mučnina (38,3%), povraćanje (33%) i omaglica (30,2%).
The most frequently observed adverse reactions (in at least 5% of patients treated with Eylea) were conjunctival haemorrhage (25%), visual acuity reduced (11%), eye pain (10%), cataract (8%), intraocular pressure increased (8%), vitreous detachment (7%) and vitreous floaters (7%).
Najčešće opažene nuspojave (u najmanje 5% bolesnika liječenih lijekom Eylea) bile su krvarenje spojnice (25%), smanjena oštrina vida (11%), bol u oku (10%), katarakta (8%), povećanje intraokularnog tlaka (8%), odignuće staklovine (7%) i opaciteti u staklovini (7%).
The most frequently observed adverse reactions (in at least 5% of patients treated with Eylea) were conjunctival haemorrhage (25%), visual acuity reduced (11%), eye pain (10%), cataract (8%), intraocular pressure increased (8%), vitreous detachment (7%), and vitreous floaters (7%).
Najčešće opažene nuspojave (u najmanje 5% bolesnika liječenih lijekom Eylea) bile su krvarenje spojnice (25%), smanjena oštrina vida (11%), bol u oku (10%), katarakta (8%), povećanje intraokularnog tlaka (8%), odignuće staklovine (7%) i opaciteti u staklovini (7%).
The most frequently observed adverse reactions (≥ 10%) in patients receiving Xofigo were diarrhoea, nausea, vomiting and thrombocytopenia.
Najčešće opažene nuspojave (≥ 10%) u bolesnika koji su primali Xofigo bile su proljev, mučnina, povraćanje i trombocitopenija.
The most frequently observed adverse reactions ( 20 %) in clinical trials include vasodilatation (including hypotension), headache and cough.
Najčešće zabilježene nuspojave (20%) u kliničkim ispitivanjima jesu vazodilatacija (uključujući hipotenziju), glavobolja i kašalj.
The most frequently observed adverse reactions across clinical trials in patients receiving olaparib monotherapy (≥ 10%) were nausea, vomiting, diarrhoea, dyspepsia, fatigue, headache, dysgeusia, decreased appetite, dizziness, anaemia, neutropaenia, lymphopaenia, mean corpuscular volume elevation, and increase in creatinine.
Najčešće prijavljene nuspojave u svim kliničkim ispitivanjima u kojima su sudjelovale bolesnice koje su primale monoterapiju olaparibom (≥ 10%) bile su mučnina, povraćanje, proljev, dispepsija, umor, glavobolja, disgeuzija, smanjen tek, omaglica, anemija, neutropenija, limfopenija, povećanje prosječnog volumena eritrocita (MCV) i povećanje razine kreatinina.
The most frequently observed adverse reactions which occurred more frequently in the lenalidomide arm compared with the control arm in Study MCL-002 were neutropenia (50.9%), anaemia (28.7%), diarrhoea (22.8%), fatigue (21.0%), constipation (17.4%), pyrexia (16.8%), and rash (including dermatitis allergic) (16.2%).
Najčešće opažene nuspojave koje su se u ispitivanju MCL-002 pojavile češće u skupini koja je primala lenalidomid nego u kontrolnoj skupini bile su: neutropenija (50,9%), anemija (28,7%), proljev (22,8%), umor (21,0%), konstipacija (17,4%), pireksija (16,8%) i osip (uključujući alergijski dermatitis) (16,2%).
The most frequently observed malignancies, other than non-melanoma skin cancer, were prostate, melanoma, colorectal and breast cancers.
Najčešće zabilježene maligne bolesti, osim nemelanomskog karcinoma kože, bile su karcinom prostate, melanom, kolorektalni karcinom, rak dojke.
The most frequently observed OI’s in clinical studies were candidiasis, cytomegalovirus, herpes simplex, Pneumocystis carinii pneumonia, and mycobacterium avium complex.
Najčešćeoportunističke infekcije u kliničkim ispitivanjima bile su kandidijaza, infekcija citomegalovirusom, herpes simpleks infekcija, upala pluća prouzročena Pneumocystis carinii i kompleksom mycobacterium avium.
The most frequently observed side effects are:
Najčešće primjećene nuspojave su:
The most frequently occurring (≥5% of patients) adverse reactions were all in the gastrointestinal disorders system organ class.
Sve najčešće nuspojave (≥ 5% bolesnika) pripadale su među poremećaje probavnog sustava.
The most frequently occurring adverse drug reactions (ADRs) (15%) reported with dabrafenib were hyperkeratosis, headache, pyrexia, arthralgia, fatigue, nausea, papilloma, alopecia, rash and vomiting.
Najučestalije nuspojave na lijek ( 15%) prijavljene pri uporabi dabrafeniba bile su hiperkeratoza, glavobolja, pireksija, artralgija, umor, mučnina, papilom, alopecija, osip i povraćanje.
The most frequently occurring adverse drug reactions observed in clinical trials of epoetin alfa are diarrhoea, nausea, vomiting, pyrexia and headache.
Nuspojave čije je pojavljivanje najčešće opaženo u kliničkim ispitivanjima epoetina alfa su proljev, mučnina, povraćanje, pireksija i glavobolja.
The most frequently occurring adverse events were fatigue; gastrointestinal disorders; haematological disorders; respiratory disorders; nervous system disorders; and pyrexia.
Najčešće nuspojave su bile umor, poremećaji probavnoga sustava, hematološki, respiratorni i neurološki poremećaji i pireksija.
The most frequently occurring adverse reactions are flatulence and constipation, found within the gastrointestinal disorders system organ class.
Najčešće nuspojave su flatulencija i konstipacija, koje prema klasifikaciji organskih sustava pripadaju poremećajima probavnog sustava.
The most frequently occurring adverse reactions with a higher incidence in the memantine group than in the placebo group were dizziness (6.3 % vs 5.6 %, respectively), headache (5.2 % vs 3.9 %), constipation (4.6 % vs 2.6 %), somnolence (3.4 % vs 2.2 %) and hypertension (4.1 % vs 2.8 %).
Nuspojave koje su se najčešće pojavljivale s većom incidencijom u skupini bolesnika liječenih memantinom nego u skupini koja je uzimala placebo bile su omaglica (6,3 % naspram 5,6 %), glavobolja (5,2 % naspram 3,9 %), konstipacija (4,6 % naspram 2,6 %), somnolencija (3,4 % naspram 2,2 %) i hipertenzija (4,1 % naspram 2,8 %).
The most frequently occurring adverse reactions with a higher incidence in the memantine group than in the placebo group were dizziness (6.3% vs 5.6%, respectively), headache (5.2% vs 3.9%), constipation (4.6% vs2.6%), somnolence (3.4% vs 2.2%) and hypertension (4.1% vs 2.8%).
Nuspojave koje su se najčešće pojavljivale s većom učestalošću u skupini bolesnika liječenih memantinom nego u skupini koja je uzimala placebo bile su omaglica (6,3% naspram 5,6%), glavobolja (5,2% naspram 3,9%), konstipacija (4,6% naspram 2,6%), somnolencija (3,4% naspram 2,2%) i hipertenzija (4,1% naspram 2,8%).
The most frequently occurring adverse reactions with a higher incidence in the Memantine Merz group than in the placebo group were dizziness (6.3% vs 5.6%, respectively), headache (5.2% vs 3.9%), constipation (4.6% vs 2.6%), somnolence (3.4% vs 2.2%) and hypertension (4.1% vs 2.8%).
Nuspojave koje su se najčešće pojavljivale s većom incidencije u skupini bolesnika liječenih Memantine Merzom nego u skupini koja je uzimala placebo bile su omaglica (6,3% naspram 5,6%), glavobolja (5,2% naspram 3,9%), konstipacija (4,6% naspram 2,6%), somnolencija (3,4% naspram 2,2%) i hipertenzija (4,1% naspram 2,8%).
The most frequently occurring adverse reactions with a higher incidence in the Memantine Merz group than in the placebo group were dizziness (6.3% vs 5.6%, respectively), headache (5.2% vs 3.9%), constipation (4.6% vs 2.6%), somnolence (3.4% vs 2.2%) and hypertension (4.1% vs 2.8%).
Nuspojave koje su se najčešće pojavljivale s većom incidencijom u skupini bolesnika liječenih Memantine Merzom nego u skupini koja je uzimala placebo bile su omaglica (6,3% naspram 5,6%), glavobolja (5,2% naspram 3,9%), konstipacija (4,6% naspram 2,6%), somnolencija (3,4% naspram 2,2%) i hipertenzija (4,1% naspram 2,8%).
The most frequently occurring serious infections in the Provenge group were catheter sepsis (0.7%), staphylococcal bacteraemia (0.7%), sepsis (0.7%), staphylococcal sepsis (0.5%), and pneumonia (0.5%).
Najčešće ozbiljne infekcije u skupini Provenge bile su kateterska sepsa (0,7%), stafilokokna bakterijemija (0,7%), sepsa (0,7%), stafilokokna sepsa (0,5%) i upala pluća (0,5%).
The most frequently occurring side effects when treating the face and scalp:
Najčešće nuspojave koje se javljaju pri liječenju lica i vlasišta:
The most frequently occurring side effects when treating the trunk and extremities:
Najčešće nuspojave koje se javljaju pri liječenju trupa i udova:
The most frequently occurring side effects with INCRELEX are: low blood sugar (hypoglycemia), vomiting, injection site reactions, headache and middle ear infections.
Nuspojave koje se najčešće javljaju s INCRELEXOM su: nizak šećer u krvi (hipoglikemija), povraćanje, reakcije na mjestu ubrizgavanja, glavobolja i infekcija srednjeg uha.
The most frequently recorded concomitant medicinal products for Parkinson’s disease in randomized patients were dopamine agonists (64%), and MAO inhibitors (37%).
Najčešće zabilježeni istodobno uzimani lijekovi za Parkinsonovu bolest u randomiziranih bolesnika bili su agonisti dopamina (64 %) i MAO inhibitori (37 %).